Bruceanic Acid A Methyl Ester
Internal ID | ec522391-0ce8-4215-90de-782ecf2cdff9 |
Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Tetracarboxylic acids and derivatives |
IUPAC Name | methyl 8-acetyl-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-11,12-dihydroxy-9-(2-methoxy-2-oxoethyl)-9-methyl-4-oxo-5,14-dioxatetracyclo[8.5.0.01,6.02,13]pentadecane-13-carboxylate |
SMILES (Canonical) | CC(C)C(=CC(=O)OC1C2C34COC2(C(C(C3C(C(CC4OC1=O)C(=O)C)(C)CC(=O)OC)O)O)C(=O)OC)C |
SMILES (Isomeric) | CC(C)/C(=C/C(=O)OC1C2C34COC2(C(C(C3C(C(CC4OC1=O)C(=O)C)(C)CC(=O)OC)O)O)C(=O)OC)/C |
InChI | InChI=1S/C28H38O12/c1-12(2)13(3)8-17(30)40-20-22-27-11-38-28(22,25(35)37-7)23(33)19(32)21(27)26(5,10-18(31)36-6)15(14(4)29)9-16(27)39-24(20)34/h8,12,15-16,19-23,32-33H,9-11H2,1-7H3/b13-8+ |
InChI Key | YGHOWFTZPVOCHA-MDWZMJQESA-N |
Popularity | 1 reference in papers |
Molecular Formula | C28H38O12 |
Molecular Weight | 566.60 g/mol |
Exact Mass | 566.23632664 g/mol |
Topological Polar Surface Area (TPSA) | 172.00 Ų |
XlogP | 1.30 |
Atomic LogP (AlogP) | 0.50 |
H-Bond Acceptor | 12 |
H-Bond Donor | 2 |
Rotatable Bonds | 7 |
53663-08-4 |
methyl 8-acetyl-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-11,12-dihydroxy-9-(2-methoxy-2-oxoethyl)-9-methyl-4-oxo-5,14-dioxatetracyclo[8.5.0.01,6.02,13]pentadecane-13-carboxylate |
NSC238184 |
BRUCEANTIN DECOMP. (B611103F121 AND K121) |
NSC 238184 |
NSC-238184 |
3,10-Ethano-1H,8H-furo(3,4-d)(1)benzopyran-9-acetic acid, 8-acetyl-4-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)octahydro-11,12-dihydroxy-3-(methoxycarbonyl)-9-methyl-5-oxo-, methyl ester, (3S-(3alpha,3aalpha,4alpha(E),6aalpha,8alpha,9beta,10alpha,10aS*,11S*,12R*))- |

Target | Value | Probability (raw) | Probability (%) |
---|---|---|---|
Human Intestinal Absorption | + | 0.9170 | 91.70% |
Caco-2 | - | 0.7770 | 77.70% |
Blood Brain Barrier | - | 0.5750 | 57.50% |
Human oral bioavailability | - | 0.7000 | 70.00% |
Subcellular localzation | Mitochondria | 0.8192 | 81.92% |
OATP2B1 inhibitior | - | 0.7195 | 71.95% |
OATP1B1 inhibitior | + | 0.8478 | 84.78% |
OATP1B3 inhibitior | + | 0.9284 | 92.84% |
MATE1 inhibitior | - | 0.9000 | 90.00% |
OCT2 inhibitior | - | 0.8500 | 85.00% |
BSEP inhibitior | + | 0.9223 | 92.23% |
P-glycoprotein inhibitior | + | 0.8098 | 80.98% |
P-glycoprotein substrate | + | 0.8427 | 84.27% |
CYP3A4 substrate | + | 0.6967 | 69.67% |
CYP2C9 substrate | - | 0.8253 | 82.53% |
CYP2D6 substrate | - | 0.8954 | 89.54% |
CYP3A4 inhibition | - | 0.8220 | 82.20% |
CYP2C9 inhibition | - | 0.8277 | 82.77% |
CYP2C19 inhibition | - | 0.8507 | 85.07% |
CYP2D6 inhibition | - | 0.9395 | 93.95% |
CYP1A2 inhibition | - | 0.8457 | 84.57% |
CYP2C8 inhibition | + | 0.4609 | 46.09% |
CYP inhibitory promiscuity | - | 0.8842 | 88.42% |
UGT catelyzed | + | 0.6000 | 60.00% |
Carcinogenicity (binary) | - | 0.9900 | 99.00% |
Carcinogenicity (trinary) | Non-required | 0.5345 | 53.45% |
Eye corrosion | - | 0.9889 | 98.89% |
Eye irritation | - | 0.9112 | 91.12% |
Skin irritation | - | 0.6188 | 61.88% |
Skin corrosion | - | 0.9405 | 94.05% |
Ames mutagenesis | - | 0.5300 | 53.00% |
Human Ether-a-go-go-Related Gene inhibition | - | 0.6351 | 63.51% |
Micronuclear | - | 0.6700 | 67.00% |
Hepatotoxicity | + | 0.5878 | 58.78% |
skin sensitisation | - | 0.8466 | 84.66% |
Respiratory toxicity | + | 0.6667 | 66.67% |
Reproductive toxicity | + | 0.8889 | 88.89% |
Mitochondrial toxicity | + | 0.7625 | 76.25% |
Nephrotoxicity | + | 0.6287 | 62.87% |
Acute Oral Toxicity (c) | I | 0.5678 | 56.78% |
Estrogen receptor binding | + | 0.7820 | 78.20% |
Androgen receptor binding | + | 0.6769 | 67.69% |
Thyroid receptor binding | - | 0.5000 | 50.00% |
Glucocorticoid receptor binding | + | 0.7731 | 77.31% |
Aromatase binding | + | 0.6799 | 67.99% |
PPAR gamma | + | 0.6801 | 68.01% |
Honey bee toxicity | - | 0.5537 | 55.37% |
Biodegradation | - | 0.7750 | 77.50% |
Crustacea aquatic toxicity | + | 0.6200 | 62.00% |
Fish aquatic toxicity | + | 0.9885 | 98.85% |
Proven Targets:
CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
---|---|---|---|---|---|
No proven targets yet! |
Predicted Targets (via Super-PRED):
CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
---|---|---|---|---|
CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.42% | 91.11% |
CHEMBL4040 | P28482 | MAP kinase ERK2 | 98.22% | 83.82% |
CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 97.24% | 96.09% |
CHEMBL1075094 | Q16236 | Nuclear factor erythroid 2-related factor 2 | 96.25% | 96.00% |
CHEMBL1293267 | Q9HC97 | G-protein coupled receptor 35 | 95.38% | 89.34% |
CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 95.28% | 94.45% |
CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 92.95% | 85.14% |
CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 92.89% | 96.47% |
CHEMBL2581 | P07339 | Cathepsin D | 92.10% | 98.95% |
CHEMBL4303 | P08238 | Heat shock protein HSP 90-beta | 91.35% | 96.77% |
CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 91.10% | 95.71% |
CHEMBL3145 | P42338 | PI3-kinase p110-beta subunit | 90.73% | 98.75% |
CHEMBL2007 | P16234 | Platelet-derived growth factor receptor alpha | 89.98% | 91.07% |
CHEMBL2373 | P21730 | C5a anaphylatoxin chemotactic receptor | 89.08% | 92.62% |
CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 88.62% | 89.50% |
CHEMBL335 | P18031 | Protein-tyrosine phosphatase 1B | 87.62% | 95.17% |
CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 87.05% | 97.25% |
CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 87.00% | 94.33% |
CHEMBL3922 | P50579 | Methionine aminopeptidase 2 | 85.98% | 97.28% |
CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 85.35% | 95.56% |
CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 85.21% | 89.00% |
CHEMBL4051 | P13569 | Cystic fibrosis transmembrane conductance regulator | 84.64% | 95.71% |
CHEMBL340 | P08684 | Cytochrome P450 3A4 | 83.64% | 91.19% |
CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 83.61% | 95.89% |
CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 83.28% | 92.88% |
CHEMBL1994 | P08235 | Mineralocorticoid receptor | 83.02% | 100.00% |
CHEMBL3437 | Q16853 | Amine oxidase, copper containing | 82.93% | 94.00% |
CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 82.74% | 99.23% |
CHEMBL4005 | P42336 | PI3-kinase p110-alpha subunit | 81.87% | 97.47% |
CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 81.82% | 96.38% |
CHEMBL255 | P29275 | Adenosine A2b receptor | 81.80% | 98.59% |
CHEMBL3137262 | O60341 | LSD1/CoREST complex | 81.36% | 97.09% |
CHEMBL299 | P17252 | Protein kinase C alpha | 80.04% | 98.03% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
Brucea antidysenterica |
PubChem | 5960381 |
LOTUS | LTS0151352 |
wikiData | Q105348092 |